CNS
-
The “Black Monday” for CNS drug-developing companies. Is the placebo “going wild and uncontrollable”?
To explore more efficient and stable clinical trial protocols, these “failures” are inevitably part of the cost
-
【Product for Licensing】siRNA Therapeutics Targeting APP for Alzheimer’s Disease (AD)
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
Brain penetrating JAK1/TYK2 inhibitors for inflammation, autoimmune and CNS diseases
If you are looking for brain-penetrating JAK1/TYK2 inhibitors, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
US biotech companies are seeking TYK2 products that can penetrate the BBB and have potential CNS indications
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
-
美国上市公司寻找能够穿透BBB而有CNS适应症潜力的TYK2产品
如果贵公司对这个机会感兴趣，请速速联系药时代BD团队！
-
【快讯】6.5亿美元！GSK与Flagship孵化的Vesalius达成多靶点战略联盟，为帕金森病患者开发突破性疗法
药时代热烈祝贺GSK和Vesalius Therapeutics！
-
GSK and Vesalius Enter Multi-Target Strategic Alliance to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Congratulations to GSK and Vesalius Therapeutics!
-
AbbVie’s stock price plummets!
Drug discovery and development is not easy at all. We pay high respect to these heroes
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
